PHPierre-Yves Hatron

Pierre-Yves Hatron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pierre-Yves Hatron has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Eric Hachulla

    Department of Internal Medicine and Clinical Immunology, Referral Centre for Rare Systemic Autoimmune Diseases North of France, North‐West, Mediterranean and Guadeloupe Centre Hospitalier Universitaire de Lille, Inserm, U1286 Lille France

    9 shared publications
  • David Launay

    CHU de Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des Maladies Auto-Immunes et Auto-inflammatoires Systémiques rares de l'Adulte du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France

    6 shared publications
  • Marc Lambert

    CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), University LILLE, F-59000 Lille, France

    6 shared publications
  • Viviane Queyrel

    5 shared publications
  • Anne-Laure Fauchais

    Department of Internal Medicine, Limoges University Hospital, Limoges, France

    4 shared publications
  • Bernard Devulder

    3 shared publications

Latest Publications

  • Open Access

    The interest of gait markers in the identification of subgroups among fibromyalgia patients

    by Bernard Auvinet, Denis Chaleil, Jean Cabane, Anne Dumolard, Pierre Hatron, Robert Juvin, Michel Lanteri-Minet, Yves Mainguy, Laurence Negre-Pages, Fabien Pillard, et al.

    Fibromyalgia (FM) is a heterogeneous syndrome and its classification into subgroups calls for broad-based discussion. FM subgrouping, which aims to adapt treatment according to different subgroups, relies in part, on psychological and cognitive dysfunctions. Since motor control of gait is closely related to cognitive function, we hypothesized that gait markers could be of interest in the identification of FM patients' subgroups. This controlled study aimed at characterizing gait disorders in FM, and subgrouping FM patients according to gait markers such as stride frequency (SF), stride regularity (SR), and cranio-caudal power (CCP) which measures kinesia.


  • Pulmonary manifestations of Sjögren's syndrome

    by Pierre-Yves Hatron, Isabelle Tillie-Leblond, David Launay, Eric Hachulla, Anne Laure Fauchais, Benoît Wallaert


    • 1 May 2008
      • Vol. 35  (5) , 933-4

    Polyarteritis nodosa-related coronary aneurysms.

    by Hélène Maillard-Lefebvre, David Launay, Frédéric Mouquet, Virginia Gaxotte, Eric Hachulla, Pascal De Groote, Marc Lambert, Viviane Queyrel, Sandrine Morell-Dubois, Jean-Paul Bérégi, et al.


    • 1 November 2007
      • Vol. 34  (12) , 2423-30

    Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study.

    by Eric Hachulla, Pierre Clerson, David Launay, Marc Lambert, Sandrine Morell-Dubois, Viviane Queyrel, Pierre-Yves Hatron

    To describe the natural history of ischemic digital ulcers (DU) in systemic sclerosis (SSc). This single-center, retrospective, longitudinal study identified patients by demographic data, SSc history and type, Rodnan score, tobacco use, presence of autoantibodies, ongoing treatment, and DU history. One hundred three patients were enrolled, 46 with DU history and 57 without; 2 with DU were excluded. The mean duration of followup from the first non-Raynaud SSc symptoms was 12.3 +/- 6.3 years in patients with DU history and 12.1 +/- 7.0 years in patients without. In 43% of cases, first DU occurred within 1 year following first non-Raynaud SSc symptoms, and within 5 years in 73% of cases. In a multivariate analysis, younger patients at occurrence of first non-Raynaud SSc symptoms (HR = 0.77 per each 5 years older, 95% CI 0.66-0.90) with higher Rodnan scores (HR = 1.21 per 5 points, 95% CI 1.05-1.47) experienced earlier DU occurrences, which were delayed by vasodilator therapy (HR = 0.17, 95% CI 0.09-0.32). Patients with shorter durations between first and second DU episodes, particularly with a second episode within 2 years of the first, experienced a higher yearly incidence of DU episodes (0.85 +/- 0.57 and 0.48 +/- 0.26, respectively, if less or more than 2 yrs; p = 0.04). Throughout the duration of followup, the incidence of finger amputation was 1.2% per patient-year in patients with DU history. Patients who are young at first sign of SSc, with high Rodnan scores and without vasodilator therapy, are at high risk of developing DU. Development of DU typically occurred within 5 years of the first non-Raynaud clinical symptom of SSc in the majority of patients.


    • 15 April 2007
      • Vol. 34  (5) , 1005-11

    Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.

    by David Launay, Luc Mouthon, Eric Hachulla, Christian Pagnoux, Pascal De Groote, Martine Remy-Jardin, Regis Matran, Marc Lambert, Viviane Queyrel, Sandrine Morell-Dubois, et al.

    To determine the prevalence and characteristics of moderate to severe pulmonary hypertension (PH) in patients with systemic sclerosis (SSc) with and without interstitial lung disease (ILD). We retrospectively studied clinical and functional characteristics of 197 consecutive patients with SSc who had undergone a screening echocardiography to detect PH. Moderate to severe PH was suspected in 36 patients (18.3%) and confirmed in 32 who underwent right heart catheterization. The prevalence of PH did not differ between patients with limited and patients with diffuse cutaneous SSc. PH was detected in 12/67 (17.9%) patients without ILD vs 24/110 (21.8%) patients with ILD (p not significant). In patients with ILD, a lower PaO2 appeared as the unique independent factor significantly associated with PH, regardless of the extent of fibrosis. In 3 patients out of 9 (33.3%) with ILD and significantly restrictive disease, PH was out of proportion to the degree of fibrosis. In patients with no ILD, a higher grade of dyspnea appeared as the unique independent factor associated with PH. In patients with no ILD, altered DLCO was the sole indicator of the pulmonary function tests associated with PH (best cutoff value 72%). DLCO correlated with systolic pulmonary arterial pressure only in patients with no ILD. Prevalence of moderate to severe PH was similar in SSc patients with and those without ILD. In patients with ILD, a lower PaO2 was the unique independent indicator associated with PH. In some patients with severe ILD, PH was out of proportion to the degree of fibrosis. A linear correlation between DLCO and systolic pulmonary arterial pressure was observed only in patients without ILD. All these indicators should assist identification of patients with or without ILD requiring diagnostic procedures for PH before annual screening.


    • 1 September 2006
      • Vol. 33  (9) , 1789-801

    High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.

    by David Launay, Martine Remy-Jardin, Ulrique Michon-Pasturel, Ioana Mastora, Eric Hachulla, Marc Lambert, Valerie Delannoy, Viviane Queyrel, Alain Duhamel, Regis Matran, et al.

    To investigate the use of high resolution computed tomography (HRCT) in diagnosis of patients with fibrosing alveolitis associated with systemic sclerosis (FA-SSc), and to determine predictors of disease progression. We retrospectively studied 90 patients with SSc who had undergone an initial (Time 1) and followup (Time 2) clinical and HRCT evaluation, with a mean +/- SD interval of 5.14 +/- 2.98 years between T1 and T2. At T1, HRCT was normal in 40 patients; at T2, 34/40 (85%) continued to have a normal HRCT. For the 50 patients with FA-SSc on HRCT scan at T1, the overall disease progression comprised extension of lung changes toward the apices with worsening of lung fibrosis at T2. Among the 37 patients who had areas of isolated ground-glass opacities at T1, 25 (68%) had progression of lung fibrosis at T2. These 25 patients were mostly men, who showed a more marked decrease of diffusing capacity and a longer interval between T1 and T2. The results emphasize the good longterm prognosis indicated by a normal initial HRCT in SSc. Patients with FA-SSc with abnormal HRCT experienced progressive replacement of ground-glass opacities by honeycombing and/or traction bronchiectasis/bronchiolectasis. Ground-glass opacity is probably the first step of lung fibrosis in SSc, and treatment should be discussed even at this early stage.


    • 1 August 2006
      • Vol. 33  (8) , 1559-62

    Significance of persistent antiphospholipid antibodies in the elderly.

    by Thomas Quéméneur, Marc Lambert, Eric Hachulla, Sylvain Dubucquoi, Claudine Caron, Anne-Laure Fauchais, Bernard Devulder, Pierre-Yves Hatron

    The prevalence of anticardiolipin antibodies (aCL) and of vascular diseases increases with age, and aCL may be associated with various diseases in the elderly. So the significance of aCL in the elderly remains difficult to determine. We sought to determine the significance of persistent antiphospholipid antibodies (aPL) in the elderly. We retrospectively analyzed the files of 327 patients [149 patients with antiphospholipid syndrome (APS); 64 patients age >or= 65 yrs] with 2 positive aPL [lupus anticoagulant (LAC) and/or aCL]. The frequency of APS was 40.8% (n = 134) in our 263 young patients (< 65 yrs) and 23.4% (n = 15) in our 64 elderly patients (>or= 65 yrs). The clinical characteristics of patients with persistent aPL were the same in those under and over 65 years. LAC was positive in all but one elderly patient with APS, and occurred in this group more frequently than in the young patients (93.3% vs 44.6%; p < 0.006). The presence of LAC allowed to discriminate APS patients in our elderly population (93.3% in APS vs 48.9% in non-APS patients; p < 0.009). Interpretation of a positive determination of APL is difficult in the elderly; persistent LAC may be the most valuable biological marker of APS in the elderly.


  • Inaugural raynaud's phenomenon is associated with a multisystemic involvement during follow-up in primary sjögren's syndrome—A report of 162 patients

    by Anne Laure Fauchais, Marc Lambert, Sylvain Dubucquoi, Eric Hachulla, Ulrique Pasturel, Viviane Queyrel, Mohamed Hebbar, L Prin, Bernard Devulder, Pierre Yves Hatron

    Studies of Raynaud's phenomenon occurring in the course of primary Sjögren's syndrome are sparse and contradictory. In this retrospective study, our aim was to determine prevalence, characteristics, and clinical associations of Raynaud's phenomenon (RP) in a group of patients with primary Sjögren's syndrome (pSS), according to revised European criteria, in order to detect, at the time of diagnosis, patients with a potentially worth systemic evolution. One hundred sixty-two patients with pSS were evaluated for the presence (48%, n = 77) or absence of RP. Clinical course of RP was usually mild and caused no vascular lesions. RP was present in 42% (n = 68) at the time of pSS diagnosis. Nail-fold microscopy performed in 89 patients (55%) showed microangiopathy evocative of systemic sclerosis (SS) in ten cases. None presented clinical aspects of SS during follow-up (median 68 months). Nonerosive arthritis, cutaneous vasculitis lesions, myositis, and renal manifestations were significantly more frequent in patients with RP (p < 0.05), than were anti-Sa, anti-SSb, rheumatoid factor, and cryoglobulinemia (p < 0.05). If the RP clinical course is usually mild in pSS, this subgroup of patients should be carefully monitored because of the occurrence of extraglandular manifestations.

    • 1 March 2004
      • Vol. 31  (3) , 500-3

    Autoantibodies against alpha-fodrin in Sjögren's syndrome with neurological manifestations.

    by Jérôme De Seze, Sylvain Dubucquoi, Anne-Laure Fauchais, Eric Hachulla, Torsten Matthias, Didier Lefranc, Pierre-Yves Hatron, Patrick Vermersch, Torsten Witte

    To investigate the diagnostic value of autoantibodies against alpha-fodrin in patients with Sjögren's syndrome (SS) with neurological manifestations compared to SS patients without neurological manifestations, a control group, and patients with other neurological autoimmune diseases including systemic lupus erythematosus (SLE) with neurological manifestations and multiple sclerosis (MS). We evaluated alpha-fodrin autoantibodies in 31 patients with SS with neurological manifestations, 53 SS patients without neurological symptoms, 38 patients with SLE, 60 with MS, and 160 controls. Twenty of the 31 SS patients with neurological manifestations (64.5%) had an increased concentration of IgA and/or IgG anti-alpha-fodrin. This was not statistically different from that of SS patients without neurological symptoms (73.6%), but was higher than the number with SSA/SSB antibodies, which were found in 15 (48%) of our SS patients without neurological manifestations. When the results of the 2 tests were combined, 28 of the 31 (90.3%) patients had positive autoantibodies (alpha-fodrin and/or SSA/SSB). Alpha-fodrin antibodies were increased in 8 (13.3%) of the 60 patients with MS, in 6 (15.7%) of 38 patients with SLE, and in 10 (6.3%) of 160 controls. Our results confirm that alpha-fodrin antibodies are an additional diagnostic tool for SS. This test is of particular interest for patients with SS with neurological manifestations, in whom anti SSA/SSB antibodies are less frequently found.


    • 1 January 2004
      • Vol. 31  (1) , 88-95

    Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in peripheral blood mononuclear cells in systemic sclerosis.

    by David Launay, Jean-Philippe Peyrat, Alain Verdière, Louis Hornez, Pierre-Yves Hatron, Eric Hachulla, Bernard Devulder, Mohamed Hebbar

    To assess sialyltransferase expression in peripheral blood mononuclear cells (PBMC) of patients with systemic sclerosis (SSc) and to correlate this expression with the clinical features of the disease. Using a multiplex reverse transcription polymerase chain reaction (RT-PCR) method, we simultaneously measured the expression of 5 sialyltransferases (ST3Gal IV, ST3Gal III, ST3Gal I, ST3Gal II, and ST6Gal I) and of one reference housekeeping gene, Tata box binding protein (TBP), in PBMC of 28 patients with SSc and 18 healthy controls. Expression of each sialyltransferase was defined by the ratio sialyltransferase amplification product intensity/TBP amplification product intensity, and was evaluated according to the skin sclerosis extension and the presence of lung fibrosis and/or of pulmonary hypertension. ST3Gal I and ST6Gal I expressions were lower in patients with SSc than in healthy controls (median 0.48 vs 1.30, p < 0.0001, and 0.71 vs 1.96, p < 0.01, respectively). No difference was observed for ST3Gal III and ST3Gal IV expression. ST3Gal IV/ST6Gal I ratio was higher in SSc patients than in controls (0.37 vs 0.28, p = 0.03). ST3Gal II was either weakly or more often not expressed in both groups. Ten patients had isolated pulmonary hypertension. They had higher ST3Gal IV expression than patients without pulmonary hypertension (0.73 vs 0.29, p = 0.04) and a higher ST3Gal IV/ST6Gal I ratio than patients without pulmonary hypertension (1.03 vs 0.27, p = 0.03) and controls (1.03 vs 0.28, p = 0.02). No difference was found in the sialyltransferase expression and soluble E-selectin concentration according to the cutaneous sclerosis extension or the presence of lung fibrosis. Sialyltransferase expression is modified in PBMC of patients with SSc compared to healthy subjects. Low ST6Gal I expression associated with normal ST3Gal IV expression, resulting in a higher ST3Gal IV/ST6Gal I ratio, suggests an enhanced expression of Sialyl-LewisX at the surface of PBMC in SSc, and therefore an active interaction between activated endothelial cells and PBMC through the binding between E-selectin and Sialyl-LewisX. This suggested that higher expression of Sialyl-LewisX concerned patients with isolated pulmonary hypertension more specifically. Binding between PBMC surface Sialyl-LewisX and activated endothelial cell E-selectin might therefore play a role in the pathogenesis of SSc-related isolated pulmonary hypertension.